NLS Pharmaceutics AG
23.1.2023 14:33:52 CET | ACCESS Newswire | Press release
- The orexin deficit is believed to be the root cause of narcolepsy
- Mazindol ER is the most advanced Orexin-2 partial receptor agonist in development for the treatment of narcolepsy and other rare sleep disorders
- Mazindol ER is a first in class, unique dual mechanism of action as pan-monoamine reuptake inhibitor and strong Orexin-2 partial receptor agonist
- Phase 2 clinical trials evaluating Quilience (mazindol ER) in the treatment of narcolepsy recently concluded, meeting the primary endpoint with high statistical significance
ZURICH, SWITZERLAND / ACCESSWIRE / January 23, 2023 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced new in vitro study results demonstrating the agonist effect of mazindol ER at the Orexin-2 Receptor (OX2R). Two identical studies measuring differing concentrations of mazindol ER confirmed significant OX2R partial agonist activity at 30μM or higher. Notably, findings show that mazindol ER showed strong OX2R partial agonist activity by cellular and nuclear receptor functional assays. Results showed pEC50 (a logarithm measure of drug potency expressing a concentration that is effective in producing 50% of the maximal response) values of 4.7 to 5 for mazindol on the OX2R, indicating a strong OX2R partial agonist.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Orexin, also known as hypocretin, is a neuropeptide that regulates arousal, wakefulness, and appetite. Orexin plays a critical role in regulating the sleep-wake cycle and the most common form of narcolepsy, type 1 (NT1), in which the individual experiences brief losses of muscle tone, known as or cataplexy, is caused by a lack of orexin in the brain due to destruction of the cells that produce it. Mazindol ER is an OX2R partial agonist that was developed to address the loss of orexin signaling in NT1. Currently available treatments for NT1 only address the associated symptoms but not the underlying loss of orexin.
"This result is very encouraging for understanding the mechanism of action of mazindol ER in the treatment of narcolepsy," said Eric Konofal, MD, PhD, Chief Scientific Officer of NLS Pharmaceutics. "This is a significant add-on therapeutic option in narcolepsy type 1 that includes excessive daytime sleepiness and the sudden loss of muscle tone, or cataplexy, when a person is awake. We now know that orexin is considered to play a crucial role in the sleep-wake cycle and narcolepsy is caused by severe loss of the orexin neurotransmitter in the lateral hypothalamus."
Additional pre-clinical in vivo studies are currently underway to confirm OX2R activity. A pilot study in OXR2 KO mice animal model compared favorably with investigational drug, TAK-925, an orexin 2 receptor agonist. Supplementary studies to further characterize OX2R activity as well as activity at OX1R are planned for the first half of 2023. NLS Pharmaceutics plans to present the study results at a scientific meeting later this year.
"The unique dual mechanism of action of mazindol ER seems to represent an advantage over previously studied compounds, as mazindol ER appears to be highly effective in reducing narcolepsy symptoms without the potential side effects of a full OX2R agonist. We are very optimistic about these studies combined with the promising results of our phase 2 program," said Alex Zwyer, Chief Executive Officer of NLS Pharmaceutics.
The Phase 3 program for Quilience (mazindol ER) is currently on track to commence in mid- 2023.
About NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd. (Nasdaq: NLSP) is a global development-stage biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system, or CNS, disorders, who have unmet medical needs. Headquartered in Switzerland and founded in 2015, NLS is led by an experienced management team with a track record of developing and commercializing product candidates. For more information, please visit www.nlspharma.com.
About Quilience®
The Company's lead product candidate, Quilience®, is a proprietary extended-release formulation of mazindol (mazindol ER) and is being developed for the treatment of narcolepsy, and potentially other sleep-wake disorders such as Idiopathic Hypersomnia (IH), for which NLS recently obtained Orphan Disease Designation (ODD) from the U. S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Mazindol is a triple monoamine reuptake inhibitor and partial Orexin-2 Receptor agonist, which was used for many years to treat patients diagnosed with narcolepsy in compassionate use programs. A Phase 2 multi-center U.S. clinical study evaluating Quilience® in adult patients suffering from narcolepsy met its primary endpoint with high statistical significance and demonstrated a favorable safety and tolerability profile. NLS also successfully completed a Phase 2 study in the U.S. evaluating Nolazol® (Mazindol Controlled-Release) in adult patients suffering from ADHD. The study met all primary and secondary endpoints and Nolazol® was well-tolerated. Quilience® has received Orphan Drug Designations both in the U.S. and in Europe for the treatment of narcolepsy. Up to 1/3 of narcoleptic patients are also diagnosed with ADHD.
Safe Harbor Statement
This press release contains expressed or implied forward-looking statements pursuant to U.S. Federal securities laws. For example, NLS is using forward-looking statements when it discusses that mazindol ER appears to be highly effective in reducing narcolepsy symptoms without the potential side effects of a full OX2R agonist, the ability of mazindol ER to treat narcolepsy and the timing of the Phase 3 program for Quilience. These forward-looking statements and their implications are based on the current expectations of the management of NLS only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; NLS may encounter delays or obstacles in launching and/or successfully completing its clinical trials; NLS' products may not be approved by regulatory agencies, NLS' technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; NLS may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with NLS' process; NLS' products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; NLS' patents may not be sufficient; NLS' products may harm recipients; changes in legislation may adversely impact NLS; inability to timely develop and introduce new technologies, products and applications; and loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of NLS to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, NLS undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting NLS is contained under the heading "Risk Factors" in NLS' annual report on Form 20-F for the year ended December 31, 2021 filed with the Securities and Exchange Commission (SEC), which is available on the SEC's website, www.sec.gov, and in subsequent filings made by NLS with the SEC.
For additional information:
Marianne Lambertson (investors & media)
NLS Pharmaceutics Ltd.
+1 239.682.8500
ml@nls-pharma.com
www.nlspharmaceutics.com
SOURCE: NLS Pharmaceutics AG
View source version on accesswire.com:
https://www.accesswire.com/736231/NLS-Pharmaceutics-Announces-New-In-Vitro-Data-Reconfirming-QuiliencesR-Mazindol-ER-Unique-Dual-Mechanism-of-Action-Involving-Significant-Orexin-2-Receptor-Activity
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Global Anti-Scam Alliance Launches Scam.org with OpenAI and Key Partners12.3.2026 11:00:00 CET | Press release
AI technology meets on-the-ground expertise from leading organizations across five continents, accessible to billions of consumers in 50+ languages covering 97% of global internet users. AMSTERDAM, NL / ACCESS Newswire / March 12, 2026 / The Global Anti-Scam Alliance (GASA) launched today Scam.org, an AI-powered platform that provides scam education, prevention, detection, reporting, and victim support in over 50 languages, making it a new global hub, accessible to 97% of the world's internet users. Scam.org is powered by partnerships with OpenAI and leading cybersecurity organizations, AnyTech365, CUBE AI,Falkin, Malwarebytes, Netcraft, ReasonLabs, ScamAdviser, Scamnetic, Seraph Secure and Spamhaus. For personal victim support, Scam.org collaborates with other victim support organizations such as AARPin the USA and ANVINT in Brazil. The platform expects more organizations to join, with plans to build an even stronger and broader coalition, creating a world where people are safer from
LiberNovo: From Spring Cleaning to Physical Renewal12.3.2026 09:00:00 CET | Press release
HONG KONG, HK / ACCESS Newswire / March 12, 2026 / As the annual ritual of spring cleaning approaches, a new movement in functional design is shifting the focus from tidying desks to restoring the bodies that sit at them. LiberNovo, a pioneer in health-first design, has announced its spring initiative: a fundamental reimagining of the smart workspace that prioritizes physical fluidity over static organization. New Season, New Standards For decades, office chair ergonomics centered on the "90-degree rule"-a rigid posture that modern research suggests is counterproductive. The true culprit of office fatigue isn't just sitting; it is the lack of movement. Prolonged static positions compress the spine and reduce circulation. LiberNovo's philosophy asserts that a "Spring Reset" is incomplete if it only addresses surface-level clutter while leaving the body in a state of constant strain. Engineering Movement At the core of this movement is the LiberNovo Omni, a chair designed to master Dynam
LiberNovo Omni Wins iF DESIGN AWARD 2026 for Breakthrough Ergonomic Design12.3.2026 09:00:00 CET | Press release
HONG KONG, HK / ACCESS Newswire / March 12, 2026 / LiberNovo is proud to announce that its leading product, the LiberNovo Omni, has won the prestigious iF DESIGN AWARD 2026 in the Product Design - Beauty/Wellness category. The iF DESIGN AWARD is one of the most esteemed design competitions in the world, honoring outstanding design achievements in terms of innovation, functionality, and user experience. Developed to revolutionize the experience of sitting for long periods, the LiberNovo Omni is a product that creates a new category of seating solutions: the Dynamic Ergonomic Chair. The chair doesn't lock people into fixed positions; it accommodates natural body positions and movement throughout the day. This award-winning chair features intelligent ergonomic technologies to enhance user comfort, spinal health, and support movement. These include LiberNovo's innovative Dynamic Support, which automatically adjusts to changing postures, and an adjustable ergonomic framework designed to ens
Tenstorrent Unveils TT-QuietBox(TM) 2, the First RISC-V AI Workstation With a Fully Open-Source Stack to Deliver Teraflop-Class Inference11.3.2026 17:00:00 CET | Press release
Liquid-Cooled Desktop System Runs Models up to 120B Parameters Locally With a Fully Open-Source Stack, Starting at $9,999 SANTA CLARA, CA / ACCESS Newswire / March 11, 2026 / Tenstorrent, the AI computing company led by CEO Jim Keller, today announced TT-QuietBox™ 2 (Blackhole™). This whisper-quiet, liquid-cooled AI workstation runs models up to 120 billion parameters directly at your desk, ships with an entirely open-source software stack from compiler to kernel, and starts at $9,999. It marks the industry's first desktop AI workstation built on RISC-V architecture to deliver teraflop-class inference. The Inference Imperative The timing matters. Inference has quietly overtaken training as the dominant AI workload, now accounting for more than 55% of cloud AI infrastructure spending at $37.5 billion - and it is still accelerating. Yet, developers running these workloads face a stark choice: pay per-token cloud fees that compound as usage scales, or buy hardware locked to proprietary st
Clockwork.io Introduces A New Class of Fault Tolerance to End Failure-Driven GPU Waste in AI Training11.3.2026 14:00:00 CET | Press release
New TorchPass solution addresses a multi-million dollar challenge with AI infrastructure; uses Live GPU Migration to keep large-scale AI training running through hardware failures instead of forcing costly restarts PALO ALTO, CA / ACCESS Newswire / March 11, 2026 / Clockwork.io, the leader in Software-Driven AI Fabrics™- a programmable, vendor-neutral software layer that optimizes large-scale GPU clusters for real-time observability, fault tolerance, and deterministic performance-today announced the general availability of TorchPass Workload Fault Tolerance. This new class of software-driven fault-tolerance eliminates one of the most costly failure modes in large-scale AI training: catastrophic job restarts caused by infrastructure faults. Delivered as a core capability of the Clockwork.io FleetIQ™ platform, TorchPass applies the principles of Software-Driven AI Fabrics to distributed training, using Live GPU Migration to allow workloads to continue running through GPU failures, networ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
